A recent study published in PJMHS evaluated the mean decrease in porto-systemic encephalopathy (PSE) score in patients with hepatic encephalopathy treated with rifaximin. In all, 300 patients (Males 164 (54.7%); mean age of patients 50.07 + 11.59 years) were included in the study. There were 12.7% patients with Child’s class A, 42% with child’s class B while 45.3% with Child’s class C. Mean PSE score (Conn’s score) before treatment initiation was 3.17 + 0.721 while after completion of treatment, the score was 1.79 + 0.879. The improvement in PSE score was statistically significant among males and females, across various age groups and in patients with various classes of Child Pugh score. It was thus concluded that rifaximin is an effective treatment option in patients with cirrhosis of liver having hepatic encephalopathy and that the drug yields significant improvement in PSE score (Conn s’ score) among patients with hepatic encephalopathy.